Salute e Benessere

Director/PDMR Shareholding

DXS INTERNATIONAL PLC(AQSE: DXSP)Notification of Director / PDMR DealingDXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 30 October 2024 Mr Bob Sutcliffe, the Chairman, purchased a total of 50,000 Ordinary Shares in the Company at a price of 1.0p per share. Further, today 31 October 2024, Mr Bob...
Nasdaq GlobeNewswire
31/10/2024

Advanced Visualization Market to Hit USD 6.55 Billion by 2029 with 11.7% CAGR |…

Browse in-depth TOC on "Advanced Visualization Market" Browse in-depth TOC on "Advanced Visualization Market" 455 - Tables 54 - Figures 386 - Pages Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing advanced visualization by enabling advanced data analysis, pattern recognition, and predictive modelling, which are crucial for early disease diagnosis to improve diagnostic efficiency & accuracy. Companies are investing in leveraging AI & ML…
PR Newswire
31/10/2024

Water Flosser Market Surges to USD 1,418.81 Million by 2030, Propelled by 5.3%…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=841408 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=841408 Browse in-depth TOC on Water Flosser Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Water Flosser Market Overview Rising Awareness of Oral Health and Hygiene Consumers are increasingly aware of the importance of oral health, leading to a growing demand for...
PR Newswire
31/10/2024

Occupancy Sensor Market worth $5.20 billion in 2030 - Exclusive Report by…

Browse in-depth TOC on "Occupancy Sensor Market" 200 – Tables62 – Figures229 – Pages Browse in-depth TOC on "Occupancy Sensor Market"200 – Tables 62 – Figures 229 – Pages Occupancy Sensor Market Report Scope: The 180-360°segment is expected to grow fastest in forecast period. The 180-360°is expected to grow fastest during the forecast period due to its ability to provide full monitoring and detection capabilities in larger and more complex spaces. These sensors can cover...
PR Newswire
31/10/2024

Veterinary Vaccines Market is expected to generate a revenue of USD 27.5 Billion…

As the global veterinary vaccines market continues to witness robust growth, industry stakeholders need actionable insights to stay ahead. Our report provides an unparalleled view into the factors driving market expansion, such as rising zoonotic disease prevalence, heightened regulatory demands for vaccine quality and safety, and advances in biotechnology enabling more efficient and effective vaccine formulations. With data-driven forecasts, emerging trends, and competitive landscape analysis…
PR Newswire
31/10/2024

B.More Collaborator, Dr. Michael Bogenschutz, Awarded $15 Million NIDA Grant for…

Participants will receive manualized, non-directive clinical support and will be randomly assigned to receive a single administration of psilocybin 30 mg (high dose), psilocybin 20 mg (medium dose), or psilocybin 1 mg (low-dose control condition). Weekly urine drug screens and continuous self-report of opioid and other drug use will be collected for 24 weeks after psilocybin administration, along with measures probing OUD-related neuropsychopathology and functional outcomes. Participants will...
PR Newswire
31/10/2024

e-therapeutics Announces Business Updates and Interim Results

Ali Mortazavi, CEO, said: “We continue to make strong and rapid progress towards becoming a clinical-stage biotech company, as we advance our pipeline of novel GalOmic therapies, aiming to file our first IND submission in 2025. I am also excited about the ongoing evolution of HepNet. Our investment in AWS infrastructure demonstrates our commitment to integrating cutting-edge technologies across our platform. To further these efforts, we are thrilled to welcome Dr Lee Clewley as our...
Nasdaq GlobeNewswire
31/10/2024

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery…

Working alongside more than 50 oncologic centres, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. By using Visium HD from 10x Genomics, Cure51 aims to uncover new insights into long-term cancer survival mechanisms and build the first proprietary multi-omics database of exceptional cancer survivors. Working alongside more than 50 oncologic centres, Cure51 intends to collect and analyze tumor tissues…
PR Newswire
31/10/2024

SKF completes acquisition of John Sample Group

JSG had approximately SEK 550 million of net sales in their latest fiscal year and 85 employees, with operations in Australia, New Zealand, Indonesia and Singapore. The company will be integrated into SKF's existing lubrication management business. JSG had approximatelySEK 550 millionof net sales in their latest fiscal year and 85 employees, with operations inAustralia,New Zealand,IndonesiaandSingapore. The company will be integrated into SKF's existing lubrication management...
PR Newswire
31/10/2024

Evaxion announces business update and third quarter 2024 financial results

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include: Significant expansion of the infectious disease vaccine...
Nasdaq GlobeNewswire
31/10/2024

BioNTech to Host Innovation Series R&D Day on November 14, 2024

MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.On the day, BioNTech's leadership team will provide an overview of the Company's corporate strategy and clinical progress across its pipeline.Investors, analysts and the interested public are invited...
Nasdaq GlobeNewswire
31/10/2024

Loftware and Signant Health Announce Availability of Integrated Clinical…

The new integration supports automation in three key areas. Firstly, it allows clinical trial master data held in GxP Inventory to be transferred into the Loftware Cloud Clinical Trials platform, removing the risk of errors from manual entry processes. Secondly, print requests can be created and approved directly within the GxP Inventory application, thereby improving efficiency and usability. Finally, print status updates are then sent back from Loftware Cloud Clinical Trials to GxP Inventory…
PR Newswire
31/10/2024

PureHealth Posts Net Profit of AED 1.4 Billion and Revenues Increase of 56% for…

Hamad Al Hammadi ,Chairman of PureHealth,said : "As we progress along our defined growth trajectory, we remain dedicated to advancing the science of longevity in the pursuit of improving quality of life. The strategic acquisitions made this year have significantly strengthened PureHealth's global position as an integrated healthcare platform, granting access to a premium cross-sector ecosystem. Our performance metrics underscore our commitment to driving innovation, achieving...
PR Newswire
31/10/2024

Teva Statement on European Commission Decision; Company to Appeal

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupportedThe company intends to appeal the outcome and is fully prepared to mount its defense Teva has supported the MS community since 1996 and will not be distracted from providing access to this important standard-of-care treatment Teva works to the highest ethical standards with all our external experts and do...
Nasdaq GlobeNewswire
31/10/2024

Kling Biotherapeutics to Present Key Applications for its Primary B-Cell…

Poster two entitled 'Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells,' details the Kling-Evolve platform which enables the rapid ex vivo maturation of immortalized human B cells to identify neutralizing antibodies against escape variants. Kling-Evolve poses the potential for rapid development of countermeasures to combat and pre-emptively address evolving viruses amidst emerging…
PR Newswire
31/10/2024

Healthcare Holding Schweiz/Winterberg Acquire MVB Medizintechnik AG

Fabian Kroeher, President of the Board of Healthcare Holding Schweiz and Partner at Winterberg Advisory GmbH, stated, "We are excited to welcome MVB Medizintechnik AG into the Healthcare Holding family. This acquisition not only broadens our product offerings but also enhances our capability to deliver tailored solutions to our customers. The integration of MVB's specialized knowledge and innovative products will significantly contribute to our growth strategy." Fabian Kroeher…
PR Newswire
31/10/2024

Lecanemab data presented at CTAD on early initiation and long-term treatment…

Benefits of continued treatment with lecanemab for people with early Alzheimer's disease Benefits of continued treatment with lecanemab for people with early Alzheimer's disease Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline in CDR-SB (global cognitive and functional scale) in the lecanemab treated group was -0.45 at 18 months compared to the...
PR Newswire
31/10/2024

NANOBIOTIX to Participate in Multiple Investor Conferences in November

~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~~ Stifel Healthcare Conference, Nov 18-19 ~~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct.31, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today...
Nasdaq GlobeNewswire
31/10/2024

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of…

Dr. Yang added, "We are actively pursuing additional partnerships across Western Europe, Latin America, the Middle East, Southeast Asia, and Canada, and expect to finalize some of these agreements shortly. Meanwhile, we are communicating with the European Medicines Agency (EMA) and other agencies for additional regulatory applications for other sugemalimab indications, including Stage III NSCLC, first-line gastric cancer, and first-line esophageal squamous cell carcinoma, aiming to bring…
PR Newswire
31/10/2024

Vistin Pharma ASA: Third quarter and YTD 2024 financial results

stof October 2024Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2024.Revenue in the third quarter ended at MNOK 106 compared to MNOK 120 in Q3 2023. Sales volume in the quarter decreased compared to same quarter last year driven by lower sales volume, safety stock build and lower global Metformin prices. Revenue for first nine months of 2024 ended at MNOK 316 compared to MNOK 328 YTD last year.Third quarter EBITDA ended at record high MNOK 29...
Nasdaq GlobeNewswire
31/10/2024

Roche presents new data at CTAD, demonstrating its growing momentum in…

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer's disease related amyloid pathology with very good accuracy.In the largest worldwide clinical trial of its kind, the blood-based test showed very good accuracy in ruling out Alzheimer's pathology in those being investigated for the disease, potentially avoiding the need for further invasive and unnecessary tests.Results further demonstrate Roche's commitment to...
Nasdaq GlobeNewswire
31/10/2024

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024 . The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to...
Nasdaq GlobeNewswire
31/10/2024

New England Journal of Medicine publishes landmark phase III results for Roche's…

Itovebi TM(inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study 1The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with aPIK3CAmutation, one of the most commonly mutated genes in HR-positive disease 2 ...
Nasdaq GlobeNewswire
31/10/2024

ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

"We are grateful for TIME's recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord injury and impaired hand and arm function," said Dave Marver, CEO of ONWARD Medical. "SCI is a devastating injury that can change lives in an instant. We are hopeful ARC-EX Therapy is just the first of many innovative therapies ONWARD Medical can introduce for the benefit of the Spinal Cord Injury Community."TIME's annual list…
Nasdaq GlobeNewswire
31/10/2024
Altri  Comunicati